Commission for the Study of Creative Imagination

The Commission for the Study of Creative Imagination was an organization Al Hubbard established in 1955 to extend psychedelic work beyond medicine and the treatment of psychological illness. Although its practical activity is uncertain, its significance lies in making visible a growing conflict over what psychedelic research was for: clinical inquiry, or a broader attempt to change society and culture.

Formation and Membership

Hubbard created the Commission as a way to formalize his far-flung network of psychedelic researchers and to move beyond what he regarded as the limits of conventional medical research. Its name reflected his interest in creative imagination, rather than a narrowly clinical mission. He recruited Humphry Osmond, Abram Hoffer, Aldous Huxley, and Sidney Cohen to its board, along with about half a dozen other researchers, a philosopher, and a United Nations official. Hubbard appointed himself scientific director.

The title and Hubbard’s academic standing raised questions among some colleagues, but the response was not simply rejection. When Betty Eisner expressed concern about how he presented himself, Osmond urged her to think of Hubbard as an explorer: someone whose importance might lie in opening paths, even if he did not embody the standards of a detached, methodical scientist. The Commission thus depended on a network whose members could admire Hubbard’s initiative while remaining uneasy about his credentials and claims.

Aims Beyond Clinical Medicine

The Commission emerged from a shift in aspiration shared by Hubbard and Huxley. Their interest moved from treating individuals with psychological problems toward the possibility of treating society as a whole. That ambition sat uneasily beside the actual methods of research, which advanced person by person and experiment by experiment. In this setting, scientific method could seem less like a route to the hoped-for transformation than a constraint upon it.

Huxley’s position sharpened the disagreement. He regarded the experience opened by mescaline or LSD as too precious to subordinate to further psychological experimentation, while Osmond remained unwilling to abandon science and medicine. Osmond nevertheless participated in many of Hubbard’s sessions with prominent participants. The Commission belonged to this contested territory: it sought a wider social purpose for psychedelics without resolving how that purpose could be reconciled with empirical research.

Uncertain Scope and Institutional Fracture

The historical account does not establish how much the Commission did beyond provide a formal name and letterhead for Hubbard’s project. Its limited or uncertain institutional substance should not obscure its symbolic role. The organization made explicit a divergence between a medical approach, organized around research and treatment, and a spiritual approach that sought value beyond what empirical methods could readily measure.

The divide became tangible in 1957, when Sidney Cohen resigned only a year after joining the board. Hubbard, meanwhile, increasingly questioned science pursued for its own sake, describing his deepest aim as something outside the reach of empirical manipulation. His appointment as scientific director therefore sat in tension with his growing distance from scientific authority. Long before Timothy Leary became the public emblem of a turn from psychotherapy toward cultural change, that change in purpose was already under way in Hubbard’s circle.

Continuing Boundary Dispute

The Commission’s conflict anticipated a wider resistance to psychedelic therapy. In the later account of the field, the high-dose psychedelic model challenged familiar psychiatric practice by centering a single, potentially transformative session rather than a long course of weekly treatment. Its spiritual associations and attention to the circumstances surrounding a session also blurred divisions between science and religion, illness and health, and therapist and patient. These features made the model difficult to absorb into a profession increasingly committed to biochemical accounts of mental illness and to controlled trials.

That problem did not disappear with the Commission. Later researchers still faced the difficulty of separating a drug’s effects from participants’ expectations, the guidance they received, and the setting in which a session took place. Some described psychedelic therapy as applied mysticism, while others emphasized the need to meet scientific standards and preserve safety and rigor. The Commission’s importance is therefore less a record of a mature research institution than an early marker of the enduring question it brought into view: whether psychedelic experience could be studied as medicine while also being valued for spiritual and cultural consequences.